Drug Profile
Sotuletinib - Celgene Corporation/Novartis
Alternative Names: BLZ-945Latest Information Update: 12 Dec 2022
Price :
$50
*
At a glance
- Originator Celgene Corporation; Novartis
- Class Amides; Amines; Antineoplastics; Benzothiazoles; Cyclohexanols; Ethers; Pyridines; Small molecules
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis
- Phase I/II Solid tumours
- No development reported Bone disorders
Most Recent Events
- 05 Dec 2022 Novartis Pharmaceuticals terminates a phase I/II trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Taiwan, Japan, Israel (PO) in US, Israel, Italy, Japan, Singapore, Spain, Taiwan and Switzerland (EudraCT2015-005806-12) (NCT02829723)
- 14 Feb 2022 Adverse events and pharmacodynamics data from preclinical macaque model study in brain disorders presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 03 Dec 2020 Chemical structure information added